Michael A. Morse, MD, professor, Medicine, Department of Surgery, Duke University School of Medicine, Duke Cancer Institute, reflects on recent data in advanced colorectal cancer.
Michael A. Morse, MD, professor of medicine, Department of Surgery, Duke University School of Medicine, Duke Cancer Institute, reflects on recent data in advanced colorectal cancer (CRC).
Results from the phase II REVERCE study presented at the 2018 Gastrointestinal Cancers Symposium showed that sequencing regorafenib (Stivarga) before cetuximab (Erbitux) resulted in superior overall survival (OS) compared with the reverse sequence in patients with metastatic CRC. Administering regorafenib before cetuximab resulted in an OS of 17.4 months compared with 11.6 months in the reverse sequence. This OS benefit was mainly in the group of patients who had primary left-sided tumors and were wild-type for KRAS, NRAS, and BRAF, Morse says.
At a median follow-up at 29 months, data showed that there was a 39% reduction in the risk of death with the regorafenib-cetuximab sequence versus the cetuximab-regorafenib sequence (HR, 0.61; 95% CI, 0.39-0.96; P = .029).